DUPILUMAB VERSUS OMALIZUMAB IN
PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COEXISTING ASTHMA
(EVEREST): A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, HEAD-TO-HEAD PHASE 4 TRIAL
De Corso E, Canonica
GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert
P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S,
Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW. Dupilumab versus omalizumab
in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma
(EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
Lancet Respir Med. 2025 Dec;13(12):1067-1077. doi:
10.1016/S2213-2600(25)00287-5. Epub 2025 Sep 28. PMID: 41033334.
Recensione a cura di Foli Silvia, Medico specializzando in Allergologia
ed Immunologia Clinica, Università degli Studi di Modena e Reggio Emilia.













